/
DCF Valuation
Base-case fair value
$6.22
Intrinsic $8.29 · 25% MOS
Current price: $1.99
Base-case summary
Our base-case DCF for Protalix BioTherapeutics, Inc. (PLX) projects 10 years of free cash flow growth at 20.0% for years 1–5 and 10.0% for years 6–10, anchored to 32.6% historical FCF growth, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $13M in trailing free cash flow, this produces an intrinsic value of $8.29 per share. A 25% safety margin gives a fair value of $6.22, suggesting the stock is currently 212% undervalued against the $1.99 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$13M
Cash & equivalents
$41M
Total debt
$8M
Shares outstanding
83M